Over the last few decades' advances have been made in the introduction of new hemostatic materials. An innovative one is FastAct (Seraseal®) which is recently available and FDA approved but not investigated in oral surgery widely yet. Aim. to evaluate the hemostatic effect of FastAct (Seraseal^®) versus tranexamic acid for the management of post extraction bleeding in normal patients. Materials and methods. This study included 100 patients with single tooth to be extracted met the inclusion criteria and divided into four groups. Each group involves 25 patients, group 1 patients are negative control group and didn't receive any hemostatic agents, group 2 patients received Gelfoam only and are positive control group, group 3 received Gelfoam with Tranexamic acid and group 4 received Gelfoam with FastAct (Seraseal). The main evaluated criteria were bleeding time after dental extraction after application of FastAct (Seraseal)and comparing it with the different groups. Data were analyzed using SPSS version 20.0 software. Statistical significance was inferred at a P value ≤ 0.05. Results. Postoperative bleeding was evaluated using scores 1, 2, 3 and 4. 3 cases (12%) of G 3 and 19 cases (76%) of G 4 had score1 and 19 cases (76%) of G 2 and 22 cases (88%) of G 3 got score 2 additionally 8 cases (32%) of G 1 and 6 cases (24%) of G 2 had score3 while 17 cases (68%) of G 1 got score 4. Group 3 was better than group 2 (P1=0.003) and group 4 was better than group 2 (P2<0.001) and group 3 (P3<0.001). In addition, all the groups are better than the control group (<0.001). There was a significant difference between the four groups regarding bleeding scores. Conclusions. Our results suggest that the use of FastAct (Seraseal^®) might be a safe and effective addition to current hemostatic strategies and hemostatic agents.